Timothy Weeden

Timothy Weeden has a strong background in therapeutic discovery research for immune-mediated diseases and neuroimmunology. Timothy has over 12 years of experience at Genzyme, a Sanofi company, where they worked as a Senior Scientist, Staff Scientist, Principal Research Associate, and Senior Research Associate. In these roles, they focused on target identification, developing novel scaffolds and libraries, and identifying biomarkers and differentially expressed proteins using various analytical techniques. Timothy also has experience in antigen discovery research for immune-mediated diseases and oncology. Prior to their time at Genzyme, Weeden worked at New England Peptide, where they served as Synthesis Manager, overseeing custom peptide synthesis, and as a Synthesis and Analytical HPLC/Mass Spectrometry technician. Currently, they are the Vice President and Head of Platform Development at Dyne Therapeutics, where they have held various leadership positions since 2018.

Timothy Weeden obtained a Bachelor of Science (BS) degree in Biochemistry_Pre-Med from Bridgewater State University. Timothy attended the university from 1997 to 2000.